AU2019393372A1 — Vibegron for the treatment of overactive bladder symptoms
Assigned to Sumitomo Pharma Co Ltd · Expires 2021-05-13 · 5y expired
What this patent protects
The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.
USPTO Abstract
The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.